
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic's strong financial performance is highlighted by significant organic growth across various segments, including a 4.7% increase in Cranial & Spinal Technologies, 7.3% in Neuromodulation, and 7.1% growth in Diabetes revenues, which exceeded market expectations. The company's Cardiovascular segment demonstrated remarkable growth, particularly with Cardiac Ablation Services, which experienced a 71% increase in revenue, indicating strong demand for innovative medical solutions. Additionally, with ongoing product launches and increased international market adoption, Medtronic is poised for continued growth, particularly in the second half of the fiscal year, signaling a positive outlook for the company's future performance.
Bears say
Medtronic is facing a negative outlook primarily due to anticipated slower product uptake in key segments, compounded by supply chain disruptions and limited operating leverage, which may adversely affect revenue growth. Competition from both established firms and emerging entrants threatens the company's market share and pricing power, while delays in critical product launches may hinder its ability to capture market interest. Additionally, concerns over higher debt levels and a failure to optimize its extensive global portfolio could exacerbate financial leverage issues, further impacting profitability.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares